Nuclear Receptors: Mechanistic Insights into Endocrine Resistance in Prostate and Breast Cancers
This review focuses on the pivotal roles of nuclear receptors (NRs) in driving endocrine resistance in prostate and breast cancers. In prostate cancer (PCa), androgen receptor (AR) amplification, mutations, and altered coactivator interactions sustain tumor growth under androgen deprivation therapy...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Receptors |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2813-2564/3/4/22 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850085175375953920 |
|---|---|
| author | Macrina Beatriz Silva-Cázares Stephanie I. Nuñez-Olvera Ricardo Hernández-Barrientos Enoc Mariano Cortés-Malagón María Elizbeth Alvarez-Sánchez Jonathan Puente-Rivera |
| author_facet | Macrina Beatriz Silva-Cázares Stephanie I. Nuñez-Olvera Ricardo Hernández-Barrientos Enoc Mariano Cortés-Malagón María Elizbeth Alvarez-Sánchez Jonathan Puente-Rivera |
| author_sort | Macrina Beatriz Silva-Cázares |
| collection | DOAJ |
| description | This review focuses on the pivotal roles of nuclear receptors (NRs) in driving endocrine resistance in prostate and breast cancers. In prostate cancer (PCa), androgen receptor (AR) amplification, mutations, and altered coactivator interactions sustain tumor growth under androgen deprivation therapy (ADT), leading to castration-resistant prostate cancer (CRPC). Orphan NRs like RORβ, TLX, and COUP-TFII further contribute to CRPC by regulating stemness and therapeutic resistance mechanisms. In breast cancer, NRs, including estrogen receptor alpha (ERα), androgen receptor (AR), glucocorticoid receptor (GR), and liver receptor homolog-1 (LRH-1), modulate estrogen signaling pathways and alternative survival mechanisms like PI3K/AKT/mTOR and NFκB, promoting resistance to endocrine therapies such as tamoxifen. Understanding these NR-mediated mechanisms is critical for developing targeted therapies to overcome endocrine resistance and improve patient outcomes in hormone-dependent cancers. |
| format | Article |
| id | doaj-art-dafd5ace954a4e2f9fe4f36775b52989 |
| institution | DOAJ |
| issn | 2813-2564 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Receptors |
| spelling | doaj-art-dafd5ace954a4e2f9fe4f36775b529892025-08-20T02:43:47ZengMDPI AGReceptors2813-25642024-10-013444445610.3390/receptors3040022Nuclear Receptors: Mechanistic Insights into Endocrine Resistance in Prostate and Breast CancersMacrina Beatriz Silva-Cázares0Stephanie I. Nuñez-Olvera1Ricardo Hernández-Barrientos2Enoc Mariano Cortés-Malagón3María Elizbeth Alvarez-Sánchez4Jonathan Puente-Rivera5Unidad Académica Multidisciplinaria Región Altiplano, Universidad Autónoma de San Luis Potosí, Carr a Cedral km 5+600 Ejido San José de las Trojes, Matehuala, San Luis Potosi 78700, MexicoDepartamento de Biología Celular y Fisiología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City 04510, MexicoDepartamento de Biología Celular y Fisiología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City 04510, MexicoDivisión de Investigación, Hospital Juárez De México, Mexico City 07760, MexicoPosgrado en Ciencias Genómicas, Universidad Autónoma de la Ciudad de México (UACM), San Lorenzo 290, Col. Del Valle, Mexico City 03100, MexicoDivisión de Investigación, Hospital Juárez De México, Mexico City 07760, MexicoThis review focuses on the pivotal roles of nuclear receptors (NRs) in driving endocrine resistance in prostate and breast cancers. In prostate cancer (PCa), androgen receptor (AR) amplification, mutations, and altered coactivator interactions sustain tumor growth under androgen deprivation therapy (ADT), leading to castration-resistant prostate cancer (CRPC). Orphan NRs like RORβ, TLX, and COUP-TFII further contribute to CRPC by regulating stemness and therapeutic resistance mechanisms. In breast cancer, NRs, including estrogen receptor alpha (ERα), androgen receptor (AR), glucocorticoid receptor (GR), and liver receptor homolog-1 (LRH-1), modulate estrogen signaling pathways and alternative survival mechanisms like PI3K/AKT/mTOR and NFκB, promoting resistance to endocrine therapies such as tamoxifen. Understanding these NR-mediated mechanisms is critical for developing targeted therapies to overcome endocrine resistance and improve patient outcomes in hormone-dependent cancers.https://www.mdpi.com/2813-2564/3/4/22nuclear receptorscastration-resistant prostate cancerendocrine-resistance |
| spellingShingle | Macrina Beatriz Silva-Cázares Stephanie I. Nuñez-Olvera Ricardo Hernández-Barrientos Enoc Mariano Cortés-Malagón María Elizbeth Alvarez-Sánchez Jonathan Puente-Rivera Nuclear Receptors: Mechanistic Insights into Endocrine Resistance in Prostate and Breast Cancers Receptors nuclear receptors castration-resistant prostate cancer endocrine-resistance |
| title | Nuclear Receptors: Mechanistic Insights into Endocrine Resistance in Prostate and Breast Cancers |
| title_full | Nuclear Receptors: Mechanistic Insights into Endocrine Resistance in Prostate and Breast Cancers |
| title_fullStr | Nuclear Receptors: Mechanistic Insights into Endocrine Resistance in Prostate and Breast Cancers |
| title_full_unstemmed | Nuclear Receptors: Mechanistic Insights into Endocrine Resistance in Prostate and Breast Cancers |
| title_short | Nuclear Receptors: Mechanistic Insights into Endocrine Resistance in Prostate and Breast Cancers |
| title_sort | nuclear receptors mechanistic insights into endocrine resistance in prostate and breast cancers |
| topic | nuclear receptors castration-resistant prostate cancer endocrine-resistance |
| url | https://www.mdpi.com/2813-2564/3/4/22 |
| work_keys_str_mv | AT macrinabeatrizsilvacazares nuclearreceptorsmechanisticinsightsintoendocrineresistanceinprostateandbreastcancers AT stephanieinunezolvera nuclearreceptorsmechanisticinsightsintoendocrineresistanceinprostateandbreastcancers AT ricardohernandezbarrientos nuclearreceptorsmechanisticinsightsintoendocrineresistanceinprostateandbreastcancers AT enocmarianocortesmalagon nuclearreceptorsmechanisticinsightsintoendocrineresistanceinprostateandbreastcancers AT mariaelizbethalvarezsanchez nuclearreceptorsmechanisticinsightsintoendocrineresistanceinprostateandbreastcancers AT jonathanpuenterivera nuclearreceptorsmechanisticinsightsintoendocrineresistanceinprostateandbreastcancers |